BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 27862344)

  • 1. Diabetes mellitus after kidney transplantation in Japanese patients: The Japan Academic Consortium of Kidney Transplantation study.
    Okumi M; Unagami K; Hirai T; Shimizu T; Ishida H; Tanabe K;
    Int J Urol; 2017 Mar; 24(3):197-204. PubMed ID: 27862344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
    Chhabra D; Skaro AI; Leventhal JR; Dalal P; Shah G; Wang E; Gallon L
    Clin J Am Soc Nephrol; 2012 Mar; 7(3):504-12. PubMed ID: 22282478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open prospective study to evaluate cardiovascular risk factors and renal function in 2 dosage regimens of tacrolimus combined with mycophenolate mofetil and steroids in renal transplant patients: 5-year results.
    Chamienia A; Dębska-Ślizień A; Król E; Biedunkiewicz B; Rutkowski B
    Transplant Proc; 2014 Oct; 46(8):2714-8. PubMed ID: 25380901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term prolonged-release tacrolimus outcomes in living donor kidney transplantation: The Japan Academic Consortium of Kidney Transplantation study-II.
    Okumi M; Omoto K; Shimizu T; Shirakawa H; Unagami K; Lee T; Ishida H; Tanabe K; Takagi T
    Int J Urol; 2023 May; 30(5):483-491. PubMed ID: 36798048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rescue therapy with tacrolimus and mycophenolate mofetil does not prevent deterioration of graft function in C4d-positive chronic allograft nephropathy.
    Schwarz C; Regele H; Huttary N; Wahrmann M; Exner M; Nagy-Bojarsky K; Kletzmayr J; Hörl WH; Böhmig GA
    Wien Klin Wochenschr; 2006 Jul; 118(13-14):397-404. PubMed ID: 16865644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression.
    Narayanan M; Pankewycz O; El-Ghoroury M; Shihab F; Wiland A; McCague K; Chan L
    Transplantation; 2013 Feb; 95(4):566-72. PubMed ID: 23423268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil in pancreas transplantation.
    Gruessner RW; Sutherland DE; Drangstveit MB; Wrenshall L; Humar A; Gruessner AC
    Transplantation; 1998 Aug; 66(3):318-23. PubMed ID: 9721799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation.
    Song JL; Gao W; Zhong Y; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG; Jiang L; Yang J
    World J Gastroenterol; 2016 Feb; 22(6):2133-41. PubMed ID: 26877618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G; Burke GW; Suzart K; Roth D; Kupin W; Rosen A; Olson L; Esquenazi V; Miller J
    Transplantation; 2002 Apr; 73(7):1100-6. PubMed ID: 11965039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression.
    Luan FL; Steffick DE; Ojo AO
    Transplantation; 2011 Feb; 91(3):334-41. PubMed ID: 21242885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective clinical trial comparing two immunosuppressive regimens, tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine, in de novo renal transplant recipients: results at 6 months follow-up.
    Favi E; Citterio F; Spagnoletti G; Gargiulo A; Delreno F; Romagnoli J; Castagneto M
    Transplant Proc; 2009 May; 41(4):1152-5. PubMed ID: 19460503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.
    Wijesinha M; Hirshon JM; Terrin M; Magder L; Brown C; Stafford K; Iacono A
    JAMA Netw Open; 2019 Aug; 2(8):e1910297. PubMed ID: 31461151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ; Zhang LW; Zhao P; Bow LM; Tian J
    Int J Clin Pract Suppl; 2015 May; (183):1-7. PubMed ID: 26176848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of intravenous tacrolimus and mycophenolate mofetil as induction and maintenance immunosuppression in simultaneous pancreas--kidney recipients with previous transplants.
    Ciancio G; Miller J; Burke GW
    Clin Transplant; 2001 Apr; 15(2):142-5. PubMed ID: 11264642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.